Last week, Sarepta Therapeutics (NASDAQ:SRPT) unveiled early stage data from trials evaluating a gene therapy for Duchenne muscular dystrophy, and the results were really impressive. Based on increases in micro-dystrophin production and decreases in markers of muscle damage, the company's plan to insert a gene in patients that produces dystrophin may help over half of those diagnosed with this devastating disease.
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2024,